Interferon ?-1b-neutralizing antibodies 5 years after clinically isolated syndrome
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F11%3A00103098" target="_blank" >RIV/00843989:_____/11:00103098 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1212/WNL.0b013e31822c90d7" target="_blank" >http://dx.doi.org/10.1212/WNL.0b013e31822c90d7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/WNL.0b013e31822c90d7" target="_blank" >10.1212/WNL.0b013e31822c90d7</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Interferon ?-1b-neutralizing antibodies 5 years after clinically isolated syndrome
Popis výsledku v původním jazyce
Objective: To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon beta-1b (IFN beta-1b). Methods: In the Betaseron/Betaferon in Newly Emerging MS For Initial Treatment (BENEFIT) study, patients were randomly assigned to 250 mu g IFN beta-1b (Betaferon) or placebo subcutaneously every other day for 2 years or until diagnosis of clinically definite MS (CDMS). Patients were then offered open-label IFN beta-1b for up to 5 years. NAb status was assessed every 6 months by the myxovirus protein A induction assay. A titer >20 NU/mL was considered NAb-positive, with low (>= 20-100 NU/mL), medium (>= 100-400 NU/mL), and high (>= 400 NU/mL) titer categories. Here we examine early-treated patients, who received IFN beta-1b for up to 5 years. Results: NAbs were measured in 277 of 292 early-treated patients and detected at least once in 88 (31.8%) patients, with 53 (60.2%) reverting to
Název v anglickém jazyce
Interferon ?-1b-neutralizing antibodies 5 years after clinically isolated syndrome
Popis výsledku anglicky
Objective: To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon beta-1b (IFN beta-1b). Methods: In the Betaseron/Betaferon in Newly Emerging MS For Initial Treatment (BENEFIT) study, patients were randomly assigned to 250 mu g IFN beta-1b (Betaferon) or placebo subcutaneously every other day for 2 years or until diagnosis of clinically definite MS (CDMS). Patients were then offered open-label IFN beta-1b for up to 5 years. NAb status was assessed every 6 months by the myxovirus protein A induction assay. A titer >20 NU/mL was considered NAb-positive, with low (>= 20-100 NU/mL), medium (>= 100-400 NU/mL), and high (>= 400 NU/mL) titer categories. Here we examine early-treated patients, who received IFN beta-1b for up to 5 years. Results: NAbs were measured in 277 of 292 early-treated patients and detected at least once in 88 (31.8%) patients, with 53 (60.2%) reverting to
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neurology
ISSN
0028-3878
e-ISSN
—
Svazek periodika
77
Číslo periodika v rámci svazku
9
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
9
Strana od-do
835-843
Kód UT WoS článku
000294537000011
EID výsledku v databázi Scopus
—